Cannabix Technologies Ships First Breath-Based Multi-Drug Testing Panel (BLOZF)

Cannabix Technologies Inc. (BLO.CN, BLOZF) announced the first commercial delivery of a breath-based multi-drug testing panel aimed at workplace and safety-sensitive markets, following validation by Omega Laboratories of a laboratory-developed testing method using its Breath Collection Unit and Breath Cartridge technologies. The panel detects five drug classes covered by the U.S. Department of Transportation's federally mandated urine testing program: amphetamines/methamphetamines, cocaine, marijuana (THC), opiates and phencyclidine (PCP). Cannabix said the technology identifies recent drug use roughly 15 minutes to four hours after consumption, a shorter detection window than urine and hair tests. Target markets include workplace drug testing, criminal justice and treatment monitoring, post-incident investigations and reasonable-suspicion testing. BLOZF has traded between $0.20 and $0.67 over the past year and was recently trading at $0.24, up 0.04%.